CarolynYMullerMD

Obstetrics & Gynecology • Albuquerque, NM

Gynecologic Oncology

Professor, Obstetrics & Gynecology, University of New Mexico School of Medicine

Join to view full profile

Dr. Muller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Muller's full profile

Already have an account?

Office
1201 Camino de Salud NE
MSC 07 4025
Albuquerque, NM 87131
Phone+1 505-925-0460

Fax+1 505-925-0454

Education & Training

University of Texas Southwestern Medical CenterFellowship, Gynecologic Oncology, 1993 - 1996
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Obstetrics and Gynecology, 1988 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1988

Certifications & Licensure

NJ State Medical License 1992 - Present
NM State Medical License 2004 - 2025
TX State Medical License 1994 - 2025
PA State Medical License 1991 - 1998
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2014
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer Start of enrollment: 1998 Sep 01
Completed
Phase 1
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Jan 19
Active, not recruiting
Not Applicable
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
Active, not recruiting
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer Start of enrollment: 2012 Mar 01
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ova...
Jubilee Brown, Austin Miller, Laura L Holman, Floor Backes, Christa Nagel
Gynecologic Oncology. 2024-11-01
1 citations
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Lilian T Gien, Danielle M Enserro, Matthew S Block, Steven Waggoner, Linda R Duska
Gynecologic Oncology. 2024-07-01
4 citations
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, Ashley F Haggerty, Edwin A Alvarez
Journal of Clinical Oncology. 2024-01-10

Press Mentions

CDC Can Help Target Healthcare Resources in Rural AreasOctober 30th, 2024
Route 66 SPORE Grant to Study Uterine CancersSeptember 30th, 2024
UNM Cancer Center Opens Ovarian Cancer Clinical Trial Using HIPEC SurgeryAugust 26th, 2024
Join now to see all